Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
07/2008
07/29/2008CA2218702C Fatty acid esters as bioactive compounds
07/24/2008US20080177094 reducing an alkyl 2,4,9-trithiaadamantane-7-carboxylate to produce 7-hydroxymethyl-2,4,9-trithiaadamantane; andoxidizing 7-hydroxymethyl-2,4,9-trithiaadamantane to produce 7-carbonyl-2,4,9-trithiaadamantane; Molecular wires having 2,4,9-trithiaadamantane surface anchors
07/24/2008US20080176903 Novel Compounds with Analgesic Effect
07/24/2008US20080176880 Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile
07/24/2008US20080176869 e.g. N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; viricide in combination with other HIV/AIDS antivirals, immunomodulators, antibiotics or vaccines; AIDS
07/23/2008EP1671949B1 Substituted Pyridinylamines
07/23/2008EP1615909B1 Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
07/23/2008EP1080092B1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
07/23/2008CN100404480C Toluene methylation process
07/22/2008US7402594 isoquinoline ring joined to a phenyl ring by a chemical group that is two bonds long and at least one cation or cationic group selected from sodium, potassium, ammonium, and tetraalkylammonium; Factor Xa inhibitor; anticoagulant; straightforward and economical synthesis
07/17/2008US20080171758 Compounds and methods for the treatment of cancer
07/16/2008EP1943293A1 Light protective additive based on organic/ inorganic hybrid polymer, method for its manufacture and use thereof
07/16/2008EP1165551B1 C10 carbamoyloxy substituted taxanes as antitumor agents
07/16/2008CN101219145A Quinazoline derivatives as VEGF inhibitors
07/16/2008CN100402499C 2-iminopyrrolidine derivatives
07/15/2008US7399577 Halogenated oxime derivatives and the use thereof
07/10/2008US20080167471 comprising 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- alpha , alpha -dimethylbenzeneacetic acid hydrochloride; antiallergic agents and bronchodilators
07/10/2008US20080167469 Preparing anhydrous 4-(4-(4-(Hydroxydiphenylmethyl)-1-piperidinyl)-1-hydroxybutyl)-alpha,alpha -dimethylbenzene acetic acid hydrochloride by azeotropic distillation of the corresponding hydrate
07/09/2008EP1455756B1 Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
07/09/2008EP1220842B1 Cyclic amine compound as ccr5 antagonist
07/08/2008US7396935 p38 kinase inhibitors; inflammatory bowel disease, rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, and congestive heart failure
07/08/2008US7396847 Oxazolidinone and/or isoxazoline as antibacterial agents
07/08/2008US7396834 e.g., 3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzyl-piperazin-1-yl)methyl]benzamide; opioid delta rreceptor agonist; analgesic, hypotensive agent; pain, anxiety and functional gastrointestinal disorders, immunomodulatory activities
07/08/2008CA2582172C Preparation of arthropodicidal oxadiazines
07/08/2008CA2432131C Pyrazole compounds useful as protein kinase inhibitors
07/03/2008US20080161334 Macrolides
07/02/2008EP1939203A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
07/02/2008EP1140857B1 Synthesis of histamine dihydrochloride
07/01/2008US7393846 phosphodiesterase type 4 inhibitors; N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide; antiinflammatory agent, antiallergen; asthma or chronic obstructive pulmonary disease
06/2008
06/26/2008US20080153893 Pyrazole Carboxamides as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
06/26/2008US20080153864 Spiroazabicyclic Heterocyclic Compounds
06/26/2008US20080153823 a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy
06/25/2008EP1678499B1 Chemical compound and assay
06/25/2008CN100396785C Resoldution method for racemic compound of nucleoside enantiomorph
06/25/2008CN100396680C Vla-4 inhibitors
06/25/2008CN100396276C Compositions containing organic compounds
06/24/2008US7390818 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent
06/24/2008US7390810 Pyrazole-amine compounds useful as kinase inhibitors
06/19/2008US20080146812 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
06/18/2008EP1932543A2 Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue
06/18/2008CN101200454A Crystalline modifications of triazinylaminostilbenes
06/18/2008CN101200450A 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
06/17/2008CA2302347C 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oles, processes for their preparation and their use for medicaments
06/12/2008US20080139811 Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection
06/12/2008US20080139616 Atherosclerosis; inflammatory diseases, Alzheimer's disease, dyslipidemia, metabolic syndrome; 2-isopropyl-5-phenyl-4-[(4-phenylbutyl)amino]isothiazole-3(2H)-thione 1,1-dioxide for example
06/11/2008EP1556370B1 Method for the synthesis of a benzimidazole compound
06/11/2008EP1497266B1 Quinoline derivatives and their use as 5-ht6 ligands
06/10/2008US7384962 Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
06/10/2008US7384955 N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl-propanamide; cannabinoid CB1/CB2 receptor agonists; analgesic; in therapy, in particular in the management of pain
06/10/2008CA2427338C Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
06/10/2008CA2225896C Process for the production of enantiomerically-pure azetidine-2-carboxylic acid
06/05/2008US20080132502 Phosphatidylinositol (PI) 3-kinase (PI3K); N-[5-(5-Benzylamino-6-chloropyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide, for example; anticancer agents, cardiovascular disorders, autoimmune disorders, rheumatic diseases
06/05/2008US20080132486 Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them
06/04/2008EP1927357A2 Low hygroscopic aripiprazole (crystal E) drug substance and processes for the preparation thereof
06/04/2008EP1927356A1 Low hygroscopic aripiprazole (crystal D) drug substance and processes for the preparation thereof
06/04/2008EP1927355A1 Low hygroscopic aripiprazole (crystal F) drug substance and processes for the preparation thereof
06/04/2008CN100391930C 1, 3-propane diol derivatives as bioactive compounds
06/03/2008US7381828 Forming a salt such as a tartrate or mandelate of 6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]-dioxol-4-yl]oxy}-1-ethanol, chemical intermediates
05/2008
05/28/2008EP1925308A1 Low hygroscopic aripiprazole (crystal G) drug substance and processes for the preparation thereof
05/28/2008EP1556382B1 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof
05/28/2008CN100390153C Intermediate for producing novel pyrazine derivatives
05/27/2008US7378529 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
05/21/2008EP1603557A4 Synthesis of peloruside a and analogs thereof for use as antitumor agents
05/21/2008EP1599206A4 Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
05/21/2008CN100389115C Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
05/20/2008US7375227 May be combined with ACE inhibitors, angiotensin or endothelin receptor antagonists, vasopressin antagonists, alpha- and beta-adrenergic antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators; cardiovascular, renal, metabolic, pulmonary and psychological disorders
05/20/2008CA2432223C Pyrazole compounds useful as protein kinase inhibitors
05/20/2008CA2350801C Hiv replication inhibiting pyrimidines
05/15/2008US20080114041 Benzothiazolesulfonamides
05/15/2008US20080113972 Enzyme inhibitors of cGMP-metabolizing phosphodiesterases, for TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION; chemical synthesis
05/14/2008EP1689736A4 Biocidal siloxane coating material containing n-halogenated amine and amide functional groups
05/14/2008EP1606277B1 Imidazol-4-yl-ethynyl-pyridine derivatives
05/14/2008EP1485365B1 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
05/13/2008US7371744 Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents
05/13/2008US7371420 Method for producing an avocado unsaponifiable rich in furan lipids
05/13/2008CA2410234C 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
05/13/2008CA2196995C Spiro-azabicyclic compounds useful in therapy
05/08/2008US20080108677 Thioxothiazolidinone Compounds For Use As Pharmaceuticals
05/08/2008US20080108676 Benzothiazolecarboxamides
05/08/2008US20080108626 (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease
05/08/2008US20080108619 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
05/08/2008US20080108601 anticancer agents; catalytic hydrogenation
05/08/2008US20080108591 2-amino-3,6-dihydro-4-dimethyl-amino-6-ethyl-1,3,5-triazine hydrochloride; advanced glycosylation end-products inhibitor;antidiabetic, insulin resistance, neurodegenerative disorders, renal complications, atherosclerosis, angiopathy
05/07/2008EP1347981B1 Condensed purine derivatives as a 1 adenosine receptor antagonists
05/06/2008US7368574 crystalline hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, used as hypoglycemic, antilipemic or antidiabetic agents
05/06/2008US7368566 Process and intermediates for preparing benzazepines
05/06/2008US7368564 Bridged macrocyclic module compositions
05/01/2008US20080103148 Preventing ventilator induced pneumonia; utilizing compounds having longer half life on mucosal surfaces
05/01/2008US20080102031 4-[(4-N,N-diethylaminocarbonyl)phenyl]-spiro[2H,1-benzopyran-2,4'-piperidine; ligands of delta opioid receptor; analgesic, anxiolitic, antidepressant, analgesic; gastrointestinal disorders, neurodegenerative diseases; side effect reduction
04/2008
04/30/2008CN100384856C Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
04/29/2008US7365205 Diamine derivatives
04/29/2008US7364754 Preparing micelles entrapping photosensitive drugs; adding alkoxyorganosilane to the micelles to form complexes of silica and the micelles; subjecting the complexes of silica and micelles to alkaline hydrolysis to precipitate silica nanoparticles; isolating the precipitated nanoparticles by dialysis
04/24/2008US20080097117 chemical intermediates for making antiinflammatory agents treating autoimmune disease; 1-[2-(Fluoren-3-yl)ethyl]-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine drug
04/24/2008US20080096926 Treatment Of Cognitive Impairment Using A Selective Dopamine D1 Receptor Agonist
04/23/2008CN100383141C Pyrazolo [4,3-d] pyrimidine derivatives
04/22/2008US7361762 Process for preparing acid salts of Gemifloxacin
04/17/2008US20080091024 Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles
04/16/2008EP1911462A2 Compositions comprising a sterol absorption inhibitor
04/16/2008EP1165549B1 C7 carbamoyloxy substituted taxanes as antitumor agents
04/16/2008CN100381423C Novel piperidine derivatives as modulators of chemokine receptor CCR5
1 ... 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 ... 105